64.40
-0.8(-1.23%)
Currency In USD
| Previous Close | 65.2 |
| Open | 65.2 |
| Day High | 66.89 |
| Day Low | 64.4 |
| 52-Week High | 86.53 |
| 52-Week Low | 43.7 |
| Volume | 23,546 |
| Average Volume | 50,658 |
| Market Cap | 2.1B |
| PE | -41.55 |
| EPS | -1.55 |
| Moving Average 50 Days | 63.08 |
| Moving Average 200 Days | 63.26 |
| Change | -0.8 |
If you invested $1000 in Belite Bio, Inc (BLTE) since IPO date, it would be worth $6,081.21 as of August 23, 2025 at a share price of $64.4. Whereas If you bought $1000 worth of Belite Bio, Inc (BLTE) shares 2 years ago, it would be worth $2,047.69 as of August 23, 2025 at a share price of $64.4.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference
GlobeNewswire Inc.
Aug 06, 2025 12:00 PM GMT
SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today
Belite Bio to Host Webcast on August 11, 2025, to Discuss Second Quarter 2025 Financial Results
GlobeNewswire Inc.
Aug 04, 2025 12:00 PM GMT
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today
Belite Bio to Participate in the BTIG Virtual Biotechnology Conference
GlobeNewswire Inc.
Jul 23, 2025 12:00 PM GMT
SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today